Stockscreener 앱 받기
400.52
5.27%
20.05
시간 외 거래:
407.00
6.48
+1.62%
United Therapeutics Corp 주식(UTHR)의 최신 뉴스
Is United Therapeutics Corporation a turnaround storyLong Setup & Precise Buy Zone Identification - خودرو بانک
What’s the RSI of United Therapeutics Corporation stockIPO Watch & Proven Capital Preservation Methods - خودرو بانک
United Therapeutics EVP Mahon sells $4.2m in shares - Investing.com
United Therapeutics EVP Mahon sells $4.2m in shares By Investing.com - Investing.com UK
Oppenheimer Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
Published on: 2025-09-05 01:07:29 - خودرو بانک
Using Bollinger Bands to evaluate United Therapeutics CorporationMarket Performance Summary & Long-Term Capital Growth Strategies - Newser
UTHR: HC Wainwright & Co. Raises Price Target for United Therape - GuruFocus
Is United Therapeutics Corporation meeting your algorithmic filter criteria2025 Market Overview & Fast Moving Trade Plans - Newser
United Therapeutics stock price target raised to $500 from $400 at H.C. Wainwright - Investing.com
United Therapeutics Corporation’s volatility index tracking explainedJuly 2025 Setups & Entry Point Confirmation Signals - Newser
United Therapeutics stock price target raised to $560 from $415 at UBS - Investing.com Canada
Will United Therapeutics Corporation benefit from rate cutsQuarterly Market Summary & Reliable Price Breakout Alerts - خودرو بانک
Does United Therapeutics Corporation have declining or rising EPSJuly 2025 Closing Moves & Weekly Market Pulse Updates - khodrobank.com
What’s next for United Therapeutics Corporation stock price2025 Growth vs Value & Daily Momentum Trading Reports - Newser
How hedge fund analytics apply to United Therapeutics Corporation stock2025 Bull vs Bear & Verified Entry Point Detection - Newser
United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement - simplywall.st
Detecting support and resistance levels for United Therapeutics Corporation2025 Technical Overview & Accurate Intraday Trade Tips - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Is United Therapeutics Corporation forming a bottoming baseJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Does United Therapeutics Corporation show high probability of rebound2025 Big Picture & High Conviction Buy Zone Picks - Newser
Is United Therapeutics Corporation stock entering bullish territoryDividend Hike & Daily Entry Point Trade Alerts - Newser
Can machine learning forecast United Therapeutics Corporation recovery2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
How to build a dashboard for United Therapeutics Corporation stockWall Street Watch & Daily Stock Trend Watchlist - Newser
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
United Therapeutics: On the Rise? - timothysykes.com
Why United Just Catapulted 39%, Pulling Two Rivals With It - Investor's Business Daily
United Therapeutics Shares Soar: Will Momentum Last? - StocksToTrade
Moving Averages: Is United Therapeutics Corporation stock influenced by commodity prices2025 Pullback Review & High Accuracy Swing Trade Signals - khodrobank.com
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest? - CryptoRank
United Therapeutics stock jumps as Jefferies raises price target on IPF study - Investing.com
United Therapeutics stock hits all-time high on successful drug trial - The Business Journals
UBS Lifts United Therapeutics’ Price Target to Drive Optimism - StocksToTrade
UBS Lifts United Therapeutics Price Target Amid Positive Study Results - timothysykes.com
United’s Tyvaso surprise in IPF potentially opens $4B market - BioWorld MedTech
Why Is United Therapeutics Stock Rallying On Tuesday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics stock hits all-time high at $419.63 - Investing.com
United Therapeutics shares surge as lung disease drug meets main study goal - TradingView
PepsiCo, United Therapeutics Lead Market Cap Stock Movers on Tuesday - Investing.com
United Therapeutics shares surge after Tyvaso IPF trial hits key goal - MSN
United Therapeutics’ Stunning Leap: What’s Behind It? - StocksToTrade
United Therapeutics' TETON-2 Trial Shows Tyvaso Improves Lung Function In IPF Patients - Nasdaq
PepsiCo, Ionis Pharma, United Therapeutics - TradingView
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
United Therapeutics posts Tyvaso trial win (UTHR:NASDAQ) - Seeking Alpha
United Therapeutics Announces Positive TETON-2 Study Results - TipRanks
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Published on: 2025-09-01 20:26:35 - Newser
Published on: 2025-09-01 19:48:53 - Newser
What is United Therapeutics Corporation’s valuation compared to sectorPortfolio Return Report & Weekly Market Pulse Alerts - khodrobank.com
Measuring United Therapeutics Corporation’s beta against major indicesJuly 2025 Review & Risk Controlled Swing Trade Alerts - Newser
United Therapeutics Corporation Rebound Backed by Sentiment Shift getLinesFromResByArray error: size == 0 - 강소기업뉴스
Using flow based indicators on United Therapeutics CorporationQuarterly Growth Report & Fast Gain Swing Alerts - Newser
United Therapeutics Corporation Recovery Gathers Momentum on Chart Signals getLinesFromResByArray error: size == 0 - kangso.co.kr
Will United Therapeutics Corporation rebound enough to break evenWeekly Stock Report & Low Volatility Stock Recommendations - Newser
2.54%
자본화:
|
볼륨(24시간):